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Hemodynamic Characteristics of Patients with
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Introduction
Patients suffering from diastolic heart failure (DHF) must meet the following 3 criteria: 1) evidence of congestive heart failure, 2) normal left ventricular (LV) systolic function, and 3) evidence of abnormal LV relaxation, filling, diastolic distensibility, or diastolic stiffness ( 1 , 2 ) . DHF is a clinically heterogeneous syndrome, and patients may have different underlying pathophysiological mechanisms such as myocardial hypertrophy, fibrosis, hypertension, ischemia, diabetes mellitus, or infiltrative cardiomyopathies such as amyloidosis. Therefore, DHF patients might be expected to respond quite differently to therapeutic interventions ( 3 -6 ) . Patients with DHF are generally elderly women with increased LV mass and a history of hypertension ( 7 -10 ) . Hypertension plays an important role in DHF, and late systolic load in hypertension has been reported to cause afterload-dependent relaxation delay ( 11 -13 ) . However, hemodynamic characteristics of patients with DHF with or without hypertension have not been compared. It has been shown that NO donors that enhance NO release improve diastolic function partly by changing the systolic loading sequence in patients with excessive arterial load ( 11 ) . Therefore, using conductance methods that can provide LV stiffness, LV relaxation, and loading sequence, we evaluated the hemodynamic differences between DHF patients with or without hypertension. We also evaluated the effects of altering the loading condition using nitroglycerin on LV systolic and diastolic function and hemodynamics.
Methods

Study Groups
Twenty-eight patients (17 men and 11 women, aged 67 ± 11 years) with DHF who had been admitted to Mie University Hospital were enrolled in this study. They either belonged to the New York Heart Association symptomatic heart failure functional classes II to IV or were referred for cardiac catheterization to assess dyspnea. After the symptoms of heart failure had been relieved by therapy including diuretics, vasodilators, and β -blockers, cardiac catheterization was performed. The diagnosis of DHF was made if 2 criteria were present: 1) symptoms and signs of heart failure and 2) LV ejection fraction > 50%, obtained by echocardiography upon admission. Seventeen patients had a past history of coronary artery disease, and most of them suffered from mild myocardial infarction. Patients were excluded from this study if they had residual ischemia in their coronary artery by perfusion MRI, valvular heart disease, atrial fibrillation, regional wallmotion abnormalities, or restriction/constriction (based on right/left heart catheterization). All intravenous medications were discontinued at least 7 d before cardiac catheterization. Patients had been receiving diuretics ( n = 5), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers ( n = 14), β -blockers ( n = 12), and calcium channel blockers ( n = 4) before enrollment in the study (Table 1 ). All medications were withheld for at least 48 h before cardiac catheterization, except for diuretics. The average LV ejection fraction was 57 ± 7% (range 51-72%), and their mean plasma brain natriuretic peptide (BNP) level was 167 ± 216 pg/mL (normal range < 18 pg/mL). Written informed consent was obtained from all patients, and the protocol was approved for use by the Human Studies Subcommittee of Mie University Graduate School of Medicine.
Cardiac Catheterization Procedures
Patients underwent routine right and left heart catheterization, (4, 13, 14) . Real-time pressure-volume diagram generation and analog/digital conversion (333 Hz) were performed using a 16-bit microcomputer system (PC-9801VX, NEC Co., Tokyo, Japan). At the beginning of the study, the conductance catheter signal gain was calibrated using a thermodilution-derived stroke volume. A calibration offset (parallel conductance) was corrected by matching a conductance catheter signal at end-diastole with an end-diastolic volume measured by biplane ventriculography using an area-length method.
Study Protocol
Three sets of steady-state LV pressure-volume loops were recorded over a 12-s recording period. Arterial blood samples were collected for measurement of plasma BNP concentrations. After baseline data were measured, nitroglycerin was infused intravenously at a dose of 0.3-0.5 μg/kg/min to decrease systolic arterial pressure by around 20 mmHg. Fifteen minutes after nitroglycerin infusion, 3 sets of steadystate pressure-volume loops were recorded again.
Data Analysis
Steady-state hemodynamic measurements were determined from signal-averaged cardiac cycles, combining 5 to 10 sequential beats. Stroke volume was calculated as end-diastolic minus end-systolic volume. The monoexponential-based time constant of isovolumetric fall of LV pressure was calculated with the assumption that pressure decayed to a non-zero asymptote (15) . The LV contractile state was assessed by endsystolic elastance (Ees) using a single-beat formula, which is sensitive to changes in contractile state but relatively insensitive to changes in loading conditions (16) . Effective arterial elastance (Ea) was calculated as end-systolic pressure divided by stroke volume (17) . The LV-arterial coupling ratio was calculated as Ea divided by Ees. The total systemic resistance was calculated as end-systolic pressure divided by cardiac output (14) . The diastolic pressure-volume relation was described by an exponential equation, P= Ae βV , where P is the LV pressure, V is the LV volume, A is a curve fitting constant, and β is a stiffness constant used to quantify passive stiffness (18) . The LV total circumferential force (TCF) was calculated from (19) :
To assess loading conditions and sequences, the time from end diastole to the peak of the force was obtained.
Statistical Analysis
Data in the text and table are expressed as mean ±SD. Baseline characteristics of patients were compared using unpaired t-tests for quantitative variables and the Fisher exact test for categorical variables. The differences in hemodynamic variables before and after administration of intravenous nitroglycerin were tested by 2-way repeated ANOVA measurements with a Student-Newman-Keuls test. p values < 0.05 were considered to be statistically significant.
Results
Patients' Subset Stratification
Patients were stratified into 2 groups: hypertensive DHF and non-hypertensive DHF. Hypertensive DHF (n= 16) was defined as patients who, upon admission, had systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or a reported history of hypertension. Non-hypertensive DHF (n= 12) was defined as patients without a reported history of hypertension and whose systolic blood pressure was < 140 mmHg and diastolic blood pressure < 90 mmHg upon admission. Accordingly, systolic and diastolic blood pressures were higher in hypertensive DHF patients than in non-hypertensive DHF patients (Table 1) . Patients with hypertensive DHF had female/male distributions similar to those of non-hypertensive DHF patients but were older than non-hypertensive DHF patients (73±8 vs. 60±10 years). The number of patients with LV hypertrophy by 2-D echocardiogram was higher in hypertensive DHF than in non-hypertensive DHF, although there were no significant differences in body surface area, body mass index, or history of coronary artery disease or diabetes mellitus. There were no significant differences between groups in mean plasma BNP levels, hemoglobin A1c levels, LV ejection fraction, or prescription of antidiabetic drugs.
Baseline Hemodynamic Characteristics
Representative data of LV pressure-volume loops and the relation between LV pressure and the loading sequence are shown in Figs. 1-3 . At baseline, LV end-diastolic pressure was elevated in the both groups, while LV end-systolic pressure was higher in hypertensive DHF patients than in nonhypertensive DHF patients (Fig. 1) . The systolic loading sequence peaked in late systole in the hypertensive DHF group but in early systole in the non-hypertensive DHF group (Figs. 2, 3) . LV function and hemodynamic characteristics are summarized in Table 2 . There were no significant differences in heart rate, LV end-diastolic and end-systolic volume, stroke volume, Ees, or Ea between the two groups. The LV-arterial coupling ratio in hypertensive DHF patients was poorer than that in non-hypertensive DHF patients (1.1±0.3 vs. 0.8±0.2, p= 0.02). τ was longer in the hypertensive DHF group than in the non-hypertensive DHF group (75±14 vs. 59±11 ms), and the time to peak TCF in hypertensive DHF patients was longer than in non-hypertensive DHF patients (253±48 vs. 142±27 ms). There were no significant differences in LV stiffness assessed by curve-fitting constant and stiffness constant between the two groups.
Effect of Nitroglycerin on Cardiac Function and Hemodynamics
LV pressure-volume loops shifted downward and leftward in both groups (Fig. 1) . The systolic loading sequence in hypertensive DHF patients demonstrated a dramatically altered Hypertensive DHF Non-hypertensive DHF peak from late systole to early systole, whereas no change was seen in non-hypertensive DHF patients (Figs. 2, 3) . Changes in LV function and hemodynamic characteristics by nitroglycerin are summarized in Table 2 . The heart rate was not statistically affected by nitroglycerin in either group. LV end-systolic and end-diastolic pressure and end-diastolic volume were decreased to the same extent in both groups. LV end-systolic volume decreased in both groups, but the degree of the decrease was smaller in hypertensive DHF patients than in non-hypertensive DHF patients (Fig. 4) , resulting in the preserved stroke volume (62±21 vs. 62±21 mL) and improved ejection fraction in hypertensive DHF patients. By contrast, the stroke volume in the non-hypertensive DHF group was decreased by nitroglycerin treatment (70±30 vs. 63±30 mL). Ea decreased in the hypertensive DHF group (2.4±0.9 vs. 2.0±0.8 mmHg/mL), while there was no change in non-hypertensive DHF group. In non-hypertensive DHF patients, nitroglycerin decreased τ by 9% (59±11 vs. 54±10 ms) without changing the time to peak TCF and LV-arterial coupling ratio. Conversely, in hypertensive DHF patients, nitroglycerin shortened τ by 18% (75±14 vs. 62±13 ms), shortened time to peak TCF (253±48 vs. 181±54 ms), and improved LV-arterial coupling ratio. The improvement in LV relaxation was greater in hypertensive DHF patients than nonhypertensive DHF patients (Fig. 4) . Nitroglycerin displaced the diastolic pressure-volume relation downward and leftward, but had no significant effects on LV stiffness in both groups.
Discussion
In the present study, we examined the characteristics of cardiac function and hemodynamics and their responses to nitroglycerin in DHF patients with or without hypertension by using pressure-volume loops. At baseline, LV relaxation was more impaired in hypertensive DHF patients than in nonhypertensive DHF patients. Nitroglycerin shortened LV relaxation and preserved stroke volume due to the changed loading sequence and improved LV-arterial coupling ratio in patients with hypertensive DHF. The present results are consistent with the previous studies showing that LV relaxation was impaired in patients with hypertensive DHF compared with disease-free control subjects (18) . The excessive arterial elastance would contribute to the prolonged LV relaxation in hypertensive DHF patients. Changing the loading sequence would affect LV relaxation because LV relaxation was sensitive to late systolic load, but not to the load itself (12, 20) . We previously reported that nitroglycerin altered the peak of the loading sequence from late to early systole, which partly contributed to the shortening of LV relaxation in excessive arterial elastance (11) . Consistent with the previous report, the peak of LV force was in late systole at baseline and nitroglycerin changed the peak of the loading sequence from late to early systole in DHF patients with hypertension. With an early increase in systolic load, calcium availability is adequate to permit recruitment of additional cross-bridge formation, so the resultant stress on individual cross-bridges does not change. However, with late load increases, the availability of calcium is reduced to limit the formation of additional cross-bridges, so the stress on individual cross-bridges increases, which may delay crossbridge interaction and slow the rate of the subsequent fall in left ventricular pressure (21) . The effect of elastic recoil on LV relaxation should be considered (22) . Nitroglycerin decreased LV end-systolic volume in hypertensive DHF patients more than in non-hypertensive DHF patients (11 vs. 4 mL, p< 0.05), suggesting that elastic recoil might contribute to the shortening of LV relaxation to a greater extent in hypertensive DHF than non-hypertensive DHF (Fig. 4) . The difference of LV mass might affect LV relaxation at baseline. Intracoronary NO donors improved diastolic relaxation in normal subjects, while the hypertrophied ventricle shows no effect of intracoronary NO donors on LV contraction and relaxation (23, 24) . In the present study, nitroglycerin shortened LV relaxation in hypertensive DHF patients to a greater extent than non-hypertensive DHF patients, although the hypertensive DHF group exhibited more LV hypertrophy. Extrinsic, but not intrinsic, factors may affect the improvement of LV relaxation during nitroglycerin infusion.
Stroke volume was preserved during nitroglycerin infusion in hypertensive DHF patients despite a decrease in preload assessed by LV end-diastolic volume. Haber et al. showed that patients with excessive arterial elastance exhibited a predominant afterload reduction without a decrease in stroke volume in response to nitroglycerin (25) . Consistent with the previous study, we observed a preserved stroke volume in hypertensive DHF patients during nitroglycerin infusion. The effect of decreased Ea on stroke volume would overcome that of LV preload reduction during nitroglycerin infusion. By contrast, in non-hypertensive DHF patients, nitroglycerin had no effects on Ees, Ea, and LV-arterial coupling, resulting in a decreased stroke volume due mainly to preload reduction.
In the present study, we observed that LV diastolic stiffness was unchanged by nitroglycerin in both groups. Paulus et al. reported that the presence of an NO donor improved LV stiffness accompanied with a slight increase in end-diastolic volume and a lowered end-diastolic pressure (26) . The discrepancy of LV stiffness during nitroglycerin infusion may be due to the extrinsic forces applied by the pericardium and the right side of the heart. Because the right ventricle faces the left ventricle, elevation of right heart diastolic pressures can constrain the filling of the left ventricle, and reduction of the right heart diastolic pressure by nitroglycerin may unload the septum and improve LV distensibility (5). Thus, a calculated LV stiffness might be improved partly because of reduced external constraint by nitroglycerin. The average LV enddiastolic volume was smaller (117±39 vs. 158±34 mL), and LV end-diastolic pressure was lower, in the present study than in the previous study, suggesting a smaller contribution of external constraints.
Limitations
First, the present study was performed after patients had been treated and their symptoms were relieved. It is possible that diastolic parameters and ventricular and arterial properties at the time of catheterization were different from those upon admission. Furthermore, patients were stratified into hypertensive or non-hypertensive DHF according to the blood pressure upon admission and/or a reported history of hypertension. Therefore, we cannot deny the past history of hypertension in patients with non-hypertensive DHF.
Second, we noticed low LV end-diastolic pressure. In the present study, symptoms of heart failure were relieved after treatment with diuretics and nitrates, which improved pulmonary congestion. Although we discontinued the use of nitrates at least 7 d before the procedures, diuretics were appropriately used to treat heart failure, which may cause the low LV enddiastolic pressure at baseline.
Third, we cannot neglect the effect of autonomic reflexes after nitroglycerin infusion on LV function and hemodynamics, although the heart rate was relatively constant.
Finally, the limitations of the conductance catheter have already been acknowledged. Volume calibration was based on ventriculography, which is error-prone. However, most of the analysis required only that the same calibration be applied to both ventricular and vascular parameter data.
Conclusions
In the present study, we demonstrated the different cardiac function and hemodynamics and the response to nitroglycerin between DHF patients with and without hypertension. We clearly showed that the decrease in arterial elastance was an important factor to treat hypertensive DHF, but not nonhypertensive DHF. The present data support the conclusion that DHF is a clinically heterogeneous syndrome because of different underlying pathophysiologic mechanisms. Further studies are needed to determine therapeutic options that can adjust to underlying pathophysiologic mechanisms.
